Zervimesine exhibited meaningful improvement in behavioral, functional, cognitive, and movement measures compared to placebo -PURCHASE, N.Y., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, ...

Cognition Therapeutics (CGTX) announced that a manuscript entitled, “Phase 2 Study of Zervimesine in Participants with Mild-to-Moderate Dementia ...

A Wigan-based dementia charity is calling on the government to improve the lives of 100,000 people with Lewy body dementia in ...

Lewy body diseases (LBDs) are a class of debilitating neurodegenerative disorders linked to the abnormal aggregation of the protein α-synuclein in nerve cells. When misfolded, this protein can produce ...

Late-breaking oral presentation by a leading global authority in Dementia with Lewy bodies (DLB) to highlight updated data from Phase 2b study on neflamapimod treatment for DLB New data demonstrating ...

Health professionals and community members recently gathered at the University of Arkansas for Medical Sciences (UAMS) Donald ...

New data from a phase IIb trial extension study suggested that investigational neflamapimod led to significant improvements on key outcomes in people with dementia with Lewy bodies (DLB). In the ...

Analysis of the health status of U.S. adults ages 65 and older indicates that 2.7 million folks are living with vascular dementia (impaired supply of blood to the brain, often caused by mini-strokes) ...

The music world mourns the loss of legendary Texas singer-songwriter Joe Ely, who passed away at the age of 78 due to complications from Lewy body dementia, Parkinso ...

Florida Atlantic University's Charles E. Schmidt College of Medicine is spearheading the South Florida site for the first U.S. clinical trial for Lewy body dementia (LBD), the second-most common ...

Researchers at the University of Bath, in collaboration with the Universities of Oxford and Bristol, have developed a molecule that prevents the clumping and build-up of a protein linked to ...